BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.

Analyst Jason Zemansky of Bank of America Securities reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), reducing the price ...

Keros Therapeutics, Inc. has announced a voluntary halt in dosing for the Tropos trial, a phase 2 clinical trial of ...

JPMorgan Chase & Co. JPM reported upbeat fourth-quarter FY24 results. Reported revenue rose 11% year-on-year to $42.8 billion. Net revenue (managed) was $43.7 billion (+10% Y/Y), beating the consensus ...

European shares were higher today. The eurozone's STOXX 600 surged 1.27%, Germany's DAX 40 gained 1.53% and France's CAC 40 gained 0.95%. Spain's IBEX 35 Index gained 1.20%, while London's FTSE 100 ...

US clinical-stage pharma Keros Therapeutics today announced that it has voluntarily halted all dosing in the TROPOS trial, a ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

Hinge Bio raises $30M Series A for lupus drug; Keros halts trial dosing; Inflammasome reports eye treatment data; J&J files bladder cancer therapy; Verastem licenses KRAS drug ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

Shares of Keros Therapeutics (KROS) plunged nearly 20% in premarket trading on Wednesday, poised to hit an all-time low after ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...